highli
attenu
rabi
viru
rv
vaccin
vector
evalu
abil
protect
highli
pathogen
siv
challeng
mamua
neg
rhesu
macaqu
immun
group
four
either
rv
express
siv
gagpol
combin
rv
express
siv
env
rv
express
siv
gagpol
empti
rv
vector
eight
week
later
anim
receiv
booster
immun
heterolog
rv
express
antigen
twelv
week
postboost
anim
challeng
intraven
tcid
pathogen
siv
immun
macaqu
vaccin
group
fold
decreas
viral
set
point
compar
control
anim
gagpolenv
immun
anim
also
significantli
lower
peak
viral
load
compar
control
anim
follow
challeng
vaccin
macaqu
rapid
induct
siv
neutral
antibodi
cell
respons
variou
siv
epitop
moreov
vaccin
macaqu
bettermaintain
peripher
memori
cell
abl
mount
polyfunct
cell
respons
mucosa
find
indic
promis
rvbase
vector
import
implic
develop
efficaci
hiv
vaccin
pandem
persist
two
decad
littl
headway
made
develop
effect
vaccin
varieti
approach
develop
vaccin
attempt
review
see
although
use
recombin
adenoviru
serotyp
base
vector
express
gene
common
wherea
vaccin
studi
replic
defici
vector
simianhuman
immunodefici
viru
shiv
look
promis
rhesu
macaqu
model
similar
vaccin
fail
induc
protect
immun
respons
larg
clinic
studi
human
despit
discourag
outcom
base
find
attenu
siv
protect
anim
lethal
challeng
live
viral
vaccin
seem
promis
candid
protect
rabi
viru
rv
envelop
nonseg
neg
strand
rna
viru
attenu
form
rvbase
vaccin
vector
proven
safe
effect
rv
rel
simpl
genom
organ
encod
five
structur
protein
nucleoprotein
phosphoprotein
matrix
protein
glycoprotein
g
rnadepend
rna
polymeras
rv
lifecycl
exclus
cytoplasm
thu
abolish
concern
viru
genet
materi
integr
host
cell
genom
previous
show
combin
rvbase
vaccin
express
either
siv
gag
shiv
env
protect
shiv
challeng
although
shiv
challeng
model
rhesu
macaqu
provid
insight
valid
vaccin
strategi
siv
infect
rhesu
macaqu
induc
progress
diseas
patholog
similar
human
infect
present
studi
investig
efficaci
two
vaccin
strategi
immun
either
recombin
rv
express
siv
gagpol
combin
rv
express
siv
gagpol
rv
express
siv
env
see
decreas
viral
set
point
vaccin
anim
compar
control
addit
observ
rvbase
vaccin
induc
neutral
antibodi
product
cell
respons
increas
protect
vaccin
cohort
rv
vaccin
strain
spbnig
describ
previous
siv
gagpol
siv
env
amplifi
polymeras
chain
reaction
vent
biolab
inc
siv
env
cytoplasm
domain
cd
replac
rv
g
siv
gagpol
siv
envrvgcd
clone
pspbnig
util
bsiwi
nhei
restrict
site
figur
sequenc
confirm
dna
sequenc
infecti
rv
recov
standard
method
design
rviggagpol
rvigenv
fig
total
rhesu
macaqu
macaca
mulatta
male
femal
year
old
use
studi
anim
hous
tulan
nation
primat
research
center
accord
regul
american
associ
assess
accredit
laboratori
anim
care
aaalac
experi
review
approv
tulan
institut
anim
care
use
committe
monkey
screen
presenc
mamua
mamua
mamua
mamua
mamub
mamub
mamub
mamub
mamub
allel
use
pcrbase
techniqu
previous
describ
anim
immun
three
group
four
macaqu
day
studi
anim
immun
intramuscularli
foci
form
unit
ffu
ffu
ffu
ffu
week
studi
anim
intramuscularli
boost
heterolog
virus
ffu
rviggagpol
ffu
rviggagpol
ffu
rvigenv
ffu
rvig
week
studi
anim
challeng
intraven
tcid
siv
iv
tissu
collectionperipher
blood
intestin
lymphocyt
collect
variou
time
point
throughout
cours
studi
pbmc
sampl
obtain
heparin
edta
anticoagul
blood
sampl
time
point
week
intestin
lamina
propria
lymphocyt
lpl
obtain
jejun
pinch
biopsi
collect
endoscopi
studi
week
intracellular
cytokin
stain
perform
describ
previous
briefli
mononuclear
cell
collect
peripher
blood
jejunum
lpl
cell
stimul
peptid
amino
acid
overlap
nih
aid
research
refer
reagent
program
deriv
sivgag
cat
sivenv
cat
sivpol
cat
presenc
stimul
done
c
hour
prior
ad
brefeldin
sigma
addit
hour
posit
neg
control
cell
stimul
pma
ionomycin
sigma
media
respect
follow
stimul
cell
stain
fluoresc
label
c
min
fix
permeabil
fixationpermeabil
solut
bd
bioscienc
permeabil
cell
stain
fluoresc
label
min
cell
suspend
stabil
fix
buffer
bd
bioscienc
analyz
bd
lsrii
system
viral
rna
plasma
quantifi
commerci
bdna
signal
amplif
assay
specif
siv
rabi
viru
neutral
antibodi
titer
determin
refer
strain
transform
intern
unit
use
world
health
organ
antirabi
viru
antibodi
standard
describ
previous
vesicular
stomat
viru
neutral
antibodi
titer
determin
spbnig
refer
strain
report
serum
dilut
achiev
reduct
fociform
unit
input
viru
describ
previous
simian
immunodefici
viru
neutral
cell
line
adapt
stock
siv
measur
use
cell
kindli
provid
dr
nathaniel
r
landau
previous
describ
cell
line
cell
clone
produc
retrovir
vector
transduct
express
express
natur
transfect
contain
tatrespons
luciferas
luc
green
fluoresc
protein
gfp
report
gene
assay
stock
produc
cell
titrat
cell
briefli
tissu
cultur
infecti
dose
tcid
viru
incub
serial
dilut
serum
sampl
triplic
hr
cell
cell
ad
well
one
set
control
well
receiv
cell
viru
viru
control
anoth
set
receiv
cell
background
control
plate
incub
approxim
cell
viru
control
well
posit
gfp
express
fluoresc
microscopi
approxim
day
altern
neutral
envpseudotyp
viru
clone
measur
reduct
luciferas
report
gene
express
singl
round
infect
tzmbl
cell
nih
aid
research
refer
reagent
program
contribut
john
kapp
xiaoyun
wu
previous
describ
assay
stock
prepar
transfect
cell
titrat
tzmbl
cell
previous
describ
briefli
tcid
viru
incub
serial
dilut
serum
sampl
duplic
hr
c
freshli
trypsin
cell
ad
well
one
set
control
well
receiv
cell
viru
viru
control
anoth
set
receiv
cell
background
control
plate
incub
hour
follow
incub
either
luminesc
measur
use
britelit
luminesc
report
gene
assay
system
perkinelm
life
scienc
neutral
titer
dilut
rel
luminesc
unit
rlu
reduc
compar
viru
control
well
subtract
background
rlu
viral
load
trajectori
log
base
transform
viral
load
trajectori
analyz
framework
nlme
animalspecif
trajectori
model
sum
linear
function
intercept
slope
b
repres
longterm
behavior
hyperbol
function
c
day
repres
sharp
declin
viral
load
week
postchalleng
common
nlme
model
base
data
anim
includ
random
effect
anim
incorpor
paramet
b
animalspecif
trajectori
differ
group
trajectori
incorpor
model
fix
effect
interest
focus
longterm
behavior
group
averag
slope
longterm
linear
trend
compar
group
use
estim
fit
nlme
model
cell
count
trajectori
log
base
transform
cell
count
analyz
fit
lme
model
linear
time
trend
log
transform
cell
trajectori
model
slope
intercept
vari
group
incorpor
random
effect
anim
adjust
baselin
cell
count
comput
averag
log
transform
cell
count
challeng
longterm
siv
antibodi
trajectori
log
base
transform
antibodi
measur
week
later
analyz
fit
lme
model
similar
cell
count
except
baselin
adjust
addit
model
adjust
differ
two
experi
block
factor
addit
overal
comparison
viral
load
three
group
week
challeng
perform
use
kruscallw
test
wilcoxon
twosampl
test
use
correspond
pair
comparison
due
small
sampl
size
analys
anim
overal
anim
pair
group
comparison
exact
version
kruscallw
wilcoxon
test
use
also
week
separ
overal
comparison
siv
nab
three
group
perform
use
exact
kruscallw
test
pvalu
djust
multipl
test
use
hommel
close
test
procedur
exact
wilcoxon
twosampl
test
use
correspond
pair
comparison
data
week
analyz
valu
detect
limit
twelv
indianorigin
rhesu
macaqu
immun
two
independ
experi
anim
mhc
type
determin
mamua
neg
howev
one
control
anim
posit
mhc
class
allel
mamub
well
document
presenc
mamub
allel
reduc
plasma
viremia
allow
elit
control
viru
despit
data
includ
statist
analys
unless
otherwis
indic
anim
given
two
immun
fig
first
attenu
replicationcompet
rv
vector
second
eight
week
later
heterolog
rv
contain
vesicular
stomat
viru
vsv
g
instead
rv
g
fig
anim
challeng
iv
tissu
cultur
infecti
dose
tcid
pathogen
siv
twenti
week
initi
immun
fig
determin
whether
immun
multipl
siv
gene
would
improv
efficaci
rvbase
vaccin
vector
use
two
differ
vaccin
regimen
first
group
anim
prime
boost
vector
express
siv
gagpol
gagpol
second
group
prime
boost
two
vector
one
express
siv
gagpol
one
express
siv
env
gagpolenv
control
group
immun
boost
empti
vector
twelv
week
second
immun
rvbase
vaccin
anim
challeng
pathogen
siv
strain
order
monitor
diseas
progress
percentag
cell
peripher
blood
mononuclear
cell
pbmc
intestin
biopsi
analyz
time
pbmc
detect
rapid
loss
cell
anim
week
post
challeng
howev
popul
stabil
week
post
challeng
fig
order
determin
signific
trend
data
group
averag
estim
linear
mix
effect
lme
model
cell
count
perform
signific
differ
slope
intercept
trajectori
found
group
observ
percentag
cell
small
intestin
lymphocyt
popul
saw
rapid
profound
loss
cell
challeng
group
fig
data
indic
vaccin
abl
protect
initi
loss
cell
known
hiv
predominantli
infect
memori
cell
mainten
memori
cell
associ
better
diseas
outcom
therefor
monitor
loss
memori
cell
shown
figur
follow
challeng
decreas
percentag
target
cell
blood
anim
except
control
anim
control
anim
percentag
cell
continu
decreas
challeng
vaccine
variabl
level
target
cell
deplet
fig
preserv
memori
cell
vaccin
macaqu
also
seen
look
central
memori
cell
initi
drop
percentag
cell
slight
restor
fig
fluctuat
target
cell
follow
challeng
indic
rvbase
vaccin
contribut
mainten
andor
restor
memori
cell
also
monitor
challeng
viru
replic
measur
vaccineinduc
efficaci
indic
drop
cell
anim
becam
infect
follow
challeng
fig
order
determin
whether
overal
trend
viral
load
differ
among
vaccin
regimen
model
averag
paramet
estim
viral
load
intercept
slope
nonlinear
mix
effect
nlme
tab
notabl
empti
vector
group
posit
longterm
slope
gagpol
gagpolenv
group
small
neg
slope
averag
longterm
slope
significantli
differ
empti
vector
gagpol
empti
vector
gagpolenv
figur
overal
differ
peak
level
siv
titer
week
post
challeng
among
three
group
signific
fig
pairwis
comparison
show
differ
empti
vector
gagpolenv
anim
signific
observ
viral
set
point
week
post
challeng
gagpol
gagpolenv
immun
anim
lower
viral
titer
respect
empti
vector
control
fig
howev
overal
pairwis
signific
differ
found
among
viral
load
time
point
nonparametr
analysi
viral
set
point
valu
repeat
without
mamub
overal
differ
among
group
signific
lastli
evalu
overal
surviv
anim
day
post
challeng
detect
statist
signific
increas
rate
surviv
gagpol
gagpolenv
immun
anim
compar
empti
vector
immun
control
fig
necropsi
data
indic
caus
death
anim
aidsdefin
ill
name
encephalomyel
glomerulosclerosi
thrombosi
pneumonia
monitor
humor
immun
respons
immun
monkey
vectorspecif
fig
sivspecif
antibodi
fig
immun
regimen
induc
strong
neutral
antibodi
nab
respons
rv
two
week
follow
initi
immun
fig
two
week
follow
booster
immun
chimer
rvvsv
vector
also
detect
high
level
antivsv
nab
fig
level
neutral
antibodi
vector
decreas
time
howev
maintain
level
consid
prevent
reinfect
vector
also
quantifi
nab
titer
siv
siv
challeng
viru
siv
prior
siv
challeng
detect
nab
siv
siv
fig
howev
vaccin
regimen
includ
rvexpress
siv
env
induc
nab
respons
siv
two
week
boost
reach
titer
high
fig
threegroup
comparison
kruskalw
exact
nonparametr
test
show
nab
level
significantli
differ
immun
group
week
respect
pairwis
comparison
gagpolenv
empti
vector
week
show
level
nab
gagpolenv
group
significantli
higher
respect
follow
challeng
nab
titer
siv
increas
eight
week
gagpolenv
gagpol
immun
anim
gener
high
nab
titer
siv
fig
furthermor
gagpolenv
immun
anim
significantli
faster
nab
respons
compar
gagpol
immun
control
anim
week
post
challeng
respect
distinguish
longterm
trend
siv
nab
titer
lme
model
perform
tab
differ
group
averag
slope
significantli
differ
gagpol
empti
vector
immun
anim
gagpolenv
empti
vector
anim
although
titer
siv
lower
seen
siv
nab
titer
began
increas
earli
week
post
challeng
vaccin
anim
fig
antigen
specif
cell
respons
determin
intracellular
cytokin
stain
pbmc
stimul
ex
vivo
variou
peptid
pool
siv
gag
pol
env
six
week
th
e
first
immun
rvvector
note
greater
percentag
antigen
specif
produc
cell
gagpolenv
immun
anim
compar
gagpol
empti
vector
immun
macaqu
addit
product
induc
respons
gag
env
pol
stimul
gagpolenv
anim
fig
twelv
week
follow
booster
immun
reexamin
antigen
specif
cell
respons
interestingli
compar
gagpol
immun
control
immun
macaqu
saw
increas
respons
gag
pol
peptid
pool
anim
fig
data
indic
rvbase
vaccin
induc
broad
rang
antigenspecif
cell
likewis
two
week
follow
siv
challeng
detect
greater
number
peripher
blood
cell
produc
gagpolenv
gagpol
immun
anim
cohort
compar
control
anim
fig
interestingli
respons
pol
epitop
princip
observ
gagpolenv
immun
anim
low
level
cell
seen
gagpol
immun
anim
follow
stimul
pol
peptid
hand
respons
env
peptid
pool
equal
gagpolenv
gagpol
immun
group
week
post
challeng
data
indic
rvbase
immun
regimen
induc
broad
cell
respons
week
post
siv
challeng
empti
vector
immun
cell
respons
maintain
gagpolenv
gagpol
macaqu
week
post
challeng
fig
control
anim
gener
respons
compar
vaccin
anim
week
post
siv
challeng
fig
howev
respons
inadequ
late
control
viral
replic
control
macaqu
suggest
induct
polyfunct
cell
import
paramet
success
hiv
vaccin
thu
addit
includ
intracellular
cytokinestain
panel
saw
three
immun
regimen
induc
polyfunct
cell
peripher
blood
env
peptid
stimulu
induc
greatest
number
polyfunct
cell
fig
howev
differ
gagpolenv
gagpol
immun
compar
empti
vector
control
follow
siv
challeng
also
isol
intestin
lymphocyt
major
siv
replic
initi
occur
gastrointestin
tract
time
challeng
week
gagpolenv
gagpol
immun
anim
cell
express
combin
two
three
cytokin
respons
gag
stimul
empti
vector
control
furthermor
two
week
postchalleng
gagpolenv
immun
anim
appreci
popul
cell
posit
four
cytokin
fig
twelv
week
postchalleng
gagpolenv
gagpol
immun
anim
greater
popul
cell
simultan
express
control
immun
anim
fig
data
indic
peripher
immun
rvbase
vaccin
ble
effici
induc
highqual
cell
mucosa
holi
grail
hiv
field
last
year
develop
effect
vaccin
import
candid
vaccin
test
simian
virus
differ
pathogen
properti
order
fulli
understand
protect
potenti
like
potenti
vaccin
rvbase
vaccin
vector
seen
efficaci
shiv
challeng
howev
oftentim
vaccin
effect
shiv
challeng
fail
protect
macaqu
pathogen
siv
studi
see
increas
surviv
vaccin
anim
siv
challeng
examin
two
differ
rvbase
vaccin
gag
gagenv
order
determin
inclus
env
vaccin
design
significantli
increas
immun
respons
amino
acid
divers
env
thu
use
env
vaccin
antigen
may
induc
protect
follow
natur
hiv
infect
see
although
gag
env
vaccine
lower
peak
viral
load
rapid
antibodi
induct
differ
vaccin
cohort
abil
maintain
low
viral
set
point
prevent
diseas
thu
appear
env
may
help
immedi
follow
infect
longterm
benefit
minim
note
siv
env
use
vaccin
siv
env
express
challeng
viru
strong
sequenc
similar
therefor
also
necessari
test
rvbase
vaccin
strategi
pathogen
challeng
heterolog
viru
siv
correl
protect
hivsiv
infect
yet
unknown
howev
evid
suggest
antibodi
cell
respons
import
passiv
transfer
varieti
antibodi
macaqu
induc
complet
partial
protect
follow
vagin
shiv
challeng
addit
decreas
hiv
level
blood
associ
high
level
hivspecif
cell
activ
cell
deplet
sivinfect
rhesu
macaqu
caus
increas
plasma
viremia
note
follow
siv
infect
natur
host
gener
absenc
chronic
immun
activ
may
need
emul
candid
vaccin
vector
order
gener
appropri
immun
use
rvbase
vaccin
vector
express
gagpol
env
siv
specif
nab
titer
detect
earli
week
boost
gagpol
env
immun
cohort
week
post
infect
vaccine
furthermor
vaccine
gener
nab
siv
siv
unclear
respons
due
vaccin
regimen
challeng
viru
howev
vaccine
clearli
show
greater
humor
immun
respons
control
note
cell
respons
also
play
central
role
control
hiv
infect
saw
peripher
secret
cell
rapidli
induc
vaccine
compar
control
addit
although
overal
profil
polyfunct
cell
blood
similar
among
immun
group
detect
larger
number
polyfunct
cell
intestin
lymphocyt
popul
vaccin
anim
may
signific
protect
mucosa
known
primari
site
viral
replic
follow
infect
one
critic
marker
hiv
vaccin
abil
reduc
viral
load
vaccin
individu
similar
vaccin
approach
saw
signific
decreas
peak
viral
load
gagpolenv
immun
group
compar
control
although
similar
decreas
induc
dna
prime
boost
vaccin
strategi
follow
siv
challeng
viral
load
vaccin
anim
began
increas
week
post
challeng
follow
rvbase
vaccin
howev
vaccin
anim
maintain
viral
load
log
lower
control
anim
week
post
challeng
anoth
ad
vaccin
strategi
serolog
distinct
ad
test
result
similar
level
siv
viral
load
reduct
see
studi
howev
appear
current
avail
vaccin
technolog
effici
combat
hiv
infect
thu
use
viral
vector
vaccin
need
revisit
addit
lower
viral
load
result
indic
rv
vaccin
protect
memori
cell
report
hivinfect
individu
maintain
memori
cell
progress
aid
likewis
restor
follow
initi
destruct
cell
compart
gut
siv
infect
macaqu
associ
long
term
nonprogress
aidslik
diseas
rvbase
vaccin
preserv
cell
express
appear
repeat
cycl
partial
restor
loss
popul
although
vaccin
complet
protect
loss
intestin
target
cell
import
note
primari
loss
intestin
cell
also
occur
nonprogress
infect
furthermor
restor
target
cell
acut
infect
import
diseas
outcom
mechan
protect
challeng
vaccin
recipi
clear
rv
vector
howev
may
due
collabor
activ
nab
cell
high
level
nab
present
gagpolenv
vaccine
time
challeng
may
respons
signific
reduct
peak
viral
load
observ
anim
howev
initi
decreas
observ
vaccin
cohort
may
also
caus
env
specif
cell
present
gagpolenv
vaccin
anim
week
postprim
delin
import
nab
rvvaccin
induc
protect
challeng
experi
use
highli
neutral
resist
siv
strain
may
use
evalu
rvbase
vaccin
may
import
consid
similar
differ
ongo
vaccin
approach
relat
rhabdoviru
vsv
seen
efficaci
shiv
yet
shown
protect
highli
pathogen
siv
strain
interest
see
differ
highli
cytotox
vsv
noncytotox
rv
note
vsv
rv
preexist
immun
human
popul
may
prove
import
one
factor
contribut
failur
step
vaccin
trial
preexist
vector
immun
addit
simplic
rv
vector
immun
schedul
two
inocul
highlight
furthermor
unlik
combin
rv
vector
vector
may
increas
observ
immun
respons
studi
indic
rvvaccin
induc
strong
humor
immun
respons
thu
suspect
rvvector
well
suit
express
novel
design
env
antigen
becom
avail
summari
result
present
indic
rvbase
vaccin
induc
potent
cellular
humor
immun
respons
macaqu
increas
immunogen
siv
antisiv
immun
respons
induc
rvvaccin
translat
increas
protect
aidslik
diseas
challeng
anim
serum
rhesu
macaqu
test
presenc
neutral
antibodi
throughout
cours
studi
neutral
antibodi
titer
rv
vsvg
b
shown
anim
neutral
tcla
siv
c
siv
measur
use
cell
altern
neutral
siv
clone
measur
tzmbl
cell
e
titer
indic
dilut
reduct
seen
compar
control
viru
pbmc
isol
rhesu
macaqu
week
postchalleng
siv
cell
stimul
ex
vivo
overlap
gag
peptid
pool
env
peptid
pool
b
pol
peptid
pool
c
altern
jejun
lymphocyt
isol
rhesu
macaqu
prechalleng
week
week
postchalleng
siv
stimul
overlap
gag
peptid
pool
ex
vivo
follow
stimul
cell
stain
presenc
segment
pie
chart
indic
proport
cell
secret
multipl
cytokin
